Advanced Miniature In-Line Blood Gas Analyzer Launched in Europe
|
By LabMedica International staff writers Posted on 31 Mar 2015 |

Image: The miniature Proxima Sensor is integrated into a patient’s arterial line to be used for directly monitoring blood gases and electrolytes over a 72 hour period as many times as required (Photo courtesy of Sphere Medical).

Image: The new Proxima in-line patient-dedicated point-of-care blood gas analyzer incorporates Proxima Sensor (in foreground) and dedicated bedside monitor (Photo courtesy of Sphere Medical).
A CE-marked patient-dedicated system, presented at ISICEM 2015, delivers point-of-care testing (POCT) by enabling critical care staff to obtain rapid and frequent laboratory-accurate arterial blood gas measurements without leaving the patient’s bedside, facilitating effective and timely clinical decisions.
Sphere Medical (Cambridge, UK) presented its Proxima System at the 35th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2015; Brussels, Belgium, March 17-20, 2015) for launch in mainland Europe. Proxima revolutionizes conventional POCT as it is attached directly to the patient through their arterial line. The miniature Proxima Sensor, containing a range of biological sensors, sits in series in the arterial line with the blood pressure transducer. For the first time, blood gas results can be delivered, like blood pressure results, within the patient’s bed space.
Proxima is simple to use, enables closed blood sampling, and is operated via the touch-screen interface of its dedicated bedside monitor. Blood is withdrawn from the patient directly into the Proxima Sensor and a panel of analytes is measured. All blood is returned to the patient – promoting blood conservation and reducing the possibility of hospital acquired anemia and subsequent transfusions. The disposable sensor can be used for monitoring blood gases and electrolytes over a 72 hour period as many times as required.
Proxima has been fully evaluated and validated in a clinical setting. A recent observational method comparison study at Queen Elizabeth Hospital (Birmingham, UK) showed excellent agreement between Proxima and hospital standard benchtop blood gas analyzers, measuring various parameters of intensive care unit (ICU) patients with a range of clinical conditions, including trauma, head injury, post-surgical recovery, and sepsis.
Dr. Tom Clutton-Brock, senior lecturer, Anaesthesia and Intensive Care Medicine, University Hospital Birmingham, said, “Rapid return of data and swift response to changing blood gases is as essential in-patient care as the continual measurement of blood pressure. Fast feedback and response could have a real impact on efficiently stabilizing patients or weaning them from mechanical ventilation.” At ISICEM 2015 Dr. Clutton-Brock presented on “Bedside Blood Analysis,” discussing how frequent measurement of arterial blood samples is a key component in the effective management of critical care patients, particularly those who are unstable. At a poster session, Dr. Clutton-Brock and Dr. Jess Fox (Sphere Medical) discussed the excellent evaluation results of the Queen Elizabeth Hospital study.
Related Links:
Sphere Medical
35th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2015)
Sphere Medical (Cambridge, UK) presented its Proxima System at the 35th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2015; Brussels, Belgium, March 17-20, 2015) for launch in mainland Europe. Proxima revolutionizes conventional POCT as it is attached directly to the patient through their arterial line. The miniature Proxima Sensor, containing a range of biological sensors, sits in series in the arterial line with the blood pressure transducer. For the first time, blood gas results can be delivered, like blood pressure results, within the patient’s bed space.
Proxima is simple to use, enables closed blood sampling, and is operated via the touch-screen interface of its dedicated bedside monitor. Blood is withdrawn from the patient directly into the Proxima Sensor and a panel of analytes is measured. All blood is returned to the patient – promoting blood conservation and reducing the possibility of hospital acquired anemia and subsequent transfusions. The disposable sensor can be used for monitoring blood gases and electrolytes over a 72 hour period as many times as required.
Proxima has been fully evaluated and validated in a clinical setting. A recent observational method comparison study at Queen Elizabeth Hospital (Birmingham, UK) showed excellent agreement between Proxima and hospital standard benchtop blood gas analyzers, measuring various parameters of intensive care unit (ICU) patients with a range of clinical conditions, including trauma, head injury, post-surgical recovery, and sepsis.
Dr. Tom Clutton-Brock, senior lecturer, Anaesthesia and Intensive Care Medicine, University Hospital Birmingham, said, “Rapid return of data and swift response to changing blood gases is as essential in-patient care as the continual measurement of blood pressure. Fast feedback and response could have a real impact on efficiently stabilizing patients or weaning them from mechanical ventilation.” At ISICEM 2015 Dr. Clutton-Brock presented on “Bedside Blood Analysis,” discussing how frequent measurement of arterial blood samples is a key component in the effective management of critical care patients, particularly those who are unstable. At a poster session, Dr. Clutton-Brock and Dr. Jess Fox (Sphere Medical) discussed the excellent evaluation results of the Queen Elizabeth Hospital study.
Related Links:
Sphere Medical
35th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2015)
Latest Hematology News
- Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
- New Marker Helps Detect Aggressive Multiple Myeloma Earlier
- New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
- AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
- Blood Test Helps Predict Short-Term Mortality After Severe Heart Attack
- Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
- Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
- Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
- Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
- Advanced CBC-Derived Indices Integrated into Hematology Platforms
- Blood Test Enables Early Detection of Multiple Myeloma Relapse
- Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
- Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
- Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
- Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
- New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
Channels
Molecular Diagnostics
view channel
Genomic Test Helps Early Breast Cancer Patients Avoid Chemotherapy
Adjuvant chemotherapy decisions in early breast cancer can expose many patients to toxicities without clear benefit when clinical factors alone do not precisely predict recurrence risk. Clinicians therefore... Read more
Residual Disease Test Predicts Merkel Cell Carcinoma Recurrence Earlier Than Antibody Assay
Merkel cell carcinoma is a rare, aggressive skin cancer with a substantial risk of relapse, occurring in about 40% of patients. Surveillance remains challenging because widely used serologic monitoring... Read moreHematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
imal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately 202,000... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read moreImmunology
view channel
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
Drug-resistant Neisseria gonorrhoeae is straining current treatment protocols and elevating the risk of complications across sexual health services. More than 500,000 cases are reported each year in the... Read more
New Rapid Ebola Antigen Test Detects Infection at Point of Care
A serious Ebola epidemic centered in the Democratic Republic of the Congo has caused hundreds of deaths and triggered a global public health emergency, with cases also reported in Uganda.... Read more
Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
U.S. health authorities have reported a rapid increase in cyclosporiasis since May 2026, with more than 1,600 confirmed infections and thousands of additional suspected cases under investigation.... Read more
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read morePathology
view channel
AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
Breast cancer diagnostic workflows increasingly depend on accurate quantification of immunohistochemical biomarkers to guide therapy selection, yet manual scoring can be variable and time-consuming.... Read more
Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
Breast cancer prognosis often depends on microscopic assessment of tumor architecture, a process that can be subjective and lead to variable predictions across patient groups. Quantitative measures that... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases
NanoSomiX, Inc. and Beckman Coulter Diagnostics announced a collaboration to explore the development of next-generation immunoassays for neurodegenerative diseases using extracellular vesicles (EVs).... Read more








